Sphingotec secures Series C financing

New antibiotic breaks resistance

Roche inks US$2bn biobucks deal with Sangamo

FDA approves cell therapy for solid tumours

Valneva licences LimmaTech’s Shigella vaccine

BI Venture Funds invests in oncolytic bacteria

GSK and Flagship Pioneering ink US$7.2bn biobucks discovery deal

Gourmey files first EU application for cell-based meat

Confo Therapeutics closes €60m Series B financing